Biotest AG: Biotest exceeds EBIT forecast in the 2019 financial year
News: Biotest AG / Key word(s): Annual Results
Biotest exceeds EBIT forecast in the 2019 financial year
Dreieich, 30 March, 2020. The Biotest Group generated sales of € 419.1 million from continuing operations in financial year 2019, compared to € 400.3 million in the previous year. This corresponds to a 4.7% increase in sales.
EBIT of continuing operations in financial year 2019 was € -1.2 million after € 10.6 million in the previous year.
As in the previous year, the core business of the Biotest Group presented in the adjusted EBIT is very profitable at € 68.6 6 million.
* The research and development cost for products that can be produced only at the new facility
Earnings before taxes (EBT) for the continuing operations of the Biotest Group amounted to € -1.3 million after € -6.0 million in the same period of the previous year.
Earnings after taxes (EAT) of the Biotest Group from continuing operations were thus € -4.7 million (same period last year: € -12.9 million). This results in earnings per ordinary share of € -0.13 € after € - 0.34 € in the previous year.
Biotest expanded the Group's own network of plasma stations again in 2019 and integrated a new collection centre in Germany, the Czech Republic and Hungary into the network of 22 stations. Hereby, the company has further expanded the strategically important self-supply with blood plasma.
As part of our Biotest Next Level expansion project, which will significantly increase both our productivity and our production capacity, the first of three approval inspections by the regulatory authorities at the Dreieich site in was passed in November 2019. The media supply to the production and the clean rooms were successfully approved by the authorities. In the next inspection planned for June 2020, the focus will be on the qualification of the production facilities, the in-process laboratories and the entire documentation of the future production operation. An inspection of the production of the so-called consistency batches is expected to accompany the production in the fourth quarter of 2020.
The forecast for the financial year 2020 was prepared on the assumption that the spread of the coronavirus will not have any significant negative impact on Biotest's business performance. However, the high level of uncertainty currently prevailing with regard to the further spread of the coronavirus and possible economic consequences limits the certainty of the planning assumptions.
As an innovative company, Biotest is making immediate use of the new legal situation and is one of the first German companies to invite shareholders to a virtual general meeting on 8 May. In this way, Biotest is taking account of the legitimate interest of shareholders in comprehensive information and prompt dividend payment, while at the same time taking into account the health of shareholders in the special corona situation.
The annual report 2019 is available on the company's website at http://www.biotest.com/de/en/investor_relations/news_and_publications/publications/presentations_and_analyst_call.cfm. There will be a download available on the website of the presentation of the conference call for analysts and journalists on April 1, 2020.
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
|Phone:||0 61 03 - 8 01-0|
|Fax:||0 61 03 - 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1010533|
|End of News||DGAP News Service|